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Abstract
Background: APOE genotype is the foremost genetic factor modulating β-amyloid (Aβ) deposition and risk of sporadic
Alzheimer’s disease (AD). Here we investigated how APOE genotype influences response to anti-Aβ immunotherapy.
Methods: APPSW/PS1dE9 (APP) transgenic mice with targeted replacement of the murine Apoe gene for human APOE
alleles received 10D5 anti-Aβ or TY11-15 isotype control antibodies between the ages of 12 and 15 months.
Results: Anti-Aβ immunization decreased both the load of fibrillar plaques and the load of Aβ immunopositive plaques
in mice of all APOE backgrounds. Although the relative reduction in parenchymal Aβ plaque load was comparable across
all APOE genotypes, APP/ε4 mice showed the greatest reduction in the absolute Aβ plaque load values, given their
highest baseline. The immunization stimulated phagocytic activation of microglia, which magnitude adjusted for the
post-treatment plaque load was the greatest in APP/ε4 mice implying association between the ε4 allele and impaired Aβ
phagocytosis. Perivascular hemosiderin deposits reflecting ensued microhemorrhages were associated with vascular Aβ
(VAβ) and ubiquitously present in control mice of all APOE genotypes, although in APP/ε3 mice their incidence was the
lowest. Anti-Aβ immunization significantly reduced VAβ burden but increased the number of hemosiderin deposits
across all APOE genotypes with the strongest and the weakest effect in APP/ε2 and APP/ε3 mice, respectively.
Conclusions: Our studies indicate that APOE genotype differentially modulates microglia activation and Aβ plaque load
reduction during anti-Aβ immunotherapy. The APOE ε3 allele shows strong protective effect against immunotherapy
associated microhemorrhages; while, conversely, the APOE ε2 allele increases risk thereof.
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Background
Accumulation of β-amyloid (Aβ) in the brain is a culprit
early in Alzheimer’s disease (AD) pathogenesis, and trig-
gers down-stream neurodegenerative cascades including
inflammatory responses, intraneuronal neurofibrillary
pathology, and synaptic and neuronal loss (reviewed in
[1–3]). Susceptibility to sporadic AD is foremost modu-
lated by APOE genotype, which also influences the load of
Aβ parenchymal plaques and vascular Aβ (VAβ) deposits.
A single copy of the APOE ε4 allele endows a ~3 fold in-
crease in AD risk, and 2 APOE ε4 copies result in a ~15
fold risk increase, while an APOE ε2 allele halves AD risk
relative to 2 copies of ε3 (reviewed in [4]). Autopsy series
and more recently positron emission tomography (PET)
imaging studies of fibrillar Aβ plaque load in AD patients
have shown ε4> > ε3 > ε2 allele gradation effect on Aβ de-
position [1–3]. To counteract down-stream neurodegener-
ative effects triggered by Aβ accumulation, development
of anti-Aβ therapeutic strategies including anti-Aβ im-
munotherapy have been proposed and pursued. Several
anti-Aβ monoclonal antibodies (mAbs) have been tested
in clinical trials in AD patients and were found to signifi-
cantly reduce load of fibrillar Aβ as demonstrated using
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PET Aβ imaging [5–8]. Whether APOE genotype also
differentially modulates degree of Aβ plaque load reduc-
tion in response to anti-Aβ passive immunization remains
unknown due to limited clinical data and because preclin-
ical testing of anti-Aβ mAbs has been exclusively con-
ducted in AD transgenic (Tg) mice models expressing
wild type, murine apoE [9–12]. The main adverse effects
associated with administration of certain anti-Aβ mAbs
during clinical trials were amyloid related imaging abnor-
malities (ARIA) identified on magnetic resonance imaging
(MRI) scans. These included vasogenic edema (ARIA-E)
and cerebral microhemorrhages (ARIA-H) that in about
20% of cases are associated with clinical symptoms and
signs [13, 14]. Frequency of ARIA events and in particular
ARIA-E was significantly higher among APOE ε4 allele
carriers compared to non-carriers, making the APOE ε4
allele a risk factor for vascular complications of anti-Aβ
immunotherapy [5, 8, 14, 15]. In view of these consider-
ations, we sought to re-examine the effects of passive
immunization in APPSWE/PS1dE9 Tg mice with targeted
replacement of the murine Apoe gene for various human
APOE alleles, which expression remains controlled by the
native murine Apoe promoter [16, 17]. These Tg mouse
lines, hereafter designated as APP/ε2, APP/ε3, and APP/
ε4, reflect the differential effect of APOE alleles on the
load of Aβ parenchymal plaques and VAβ known from
AD patients [18]. The vaccination experiment was started
in 12 months. old mice with advanced load of Aβ deposits
[19, 20], to emulate the stage of human disease in regard
to Aβ deposition in which anti-Aβ immunotherapy is
currently occurring. We used mAb 10D5 direct against
Aβ3–7 epitope [10], which is known to penetrate the
blood–brain-barrier (BBB) and directly binds to deposited
Aβ triggering microglial cells to clear Aβ plaques through
Fc receptor-mediated phagocytosis [9]. Our study in
APOE humanized APPSWE/PS1dE9 mice provides evidence
for differential effect of APOE alleles on response to anti-
Aβ immunotherapy and occurrence of vascular complica-
tions associated with thereof.
Methods
All reagents and antibodies, unless stated otherwise, were
purchased from Sigma-Aldrich (St. Louis, MO).
Animals and antibody treatment
All mouse care and experimental procedures were ap-
proved by Institutional Animal Care and Use Committees
of the New York University School of Medicine and the
Washington University School of Medicine. Generation of
APP/ε2, APP/ε3, and APP/ε4 mice by cross-breeding of
APOE ε2, APOE ε3, or APOE ε4 targeted replacement mice
with APPSW/PS1dE9 mice and detailed genotyping proce-
dures have been previously described [19, 20]. This study
was performed using non-breeder mice of both sexes with
each sex contributing approximately half to the total animal
number in each experimental group. Animals separated by
sex were aged in a barrier facility with a 12/12 h. light/dark
cycle and ad libitum food and water access. The antibody
treatment in animals of all APOE backgrounds was
commenced at the age of 12 months and was carried out
continuously for three months till the animals were killed
at the age of 15 months. Anti-Aβ 10D5 mAb or TY11-15
an isotype control IgG2a antibody [9, 10, 21] were adminis-
tered once a week (10 mg/kg) through intraperitoneal injec-
tions. The dose of 10D5 mAb used in this study was
previously shown to be effective in removing Aβ plaques in
PDAPP AD Tg mice expressing wild type murine apoE [9,
10, 22]. Prior to each injection mice were weighted and the
accurate dose of administered antibodies was quantified.
Antibodies were injected diluted in 0.25 ml of sterile phos-
phate buffered saline (PBS), pH 7.4 using a 29 gauge needle.
Both 10D5 mAb and TY11-15 control IgG were produced,
purified and provided by Janssen Alzheimer Immunother-
apy. In addition to 10D5 mAb treatment and TY11-15 con-
trol groups, for each APOE genotype we analyzed a group
of age-matched mice receiving no treatment or sham injec-
tions. During the treatment all animals were closely moni-
tored for any signs of toxicity by the veterinary staff. 10D5
mAb and TY11-15 control IgG2a injections were well
tolerated by the animals, which showed no abnormalities in
the following monitored parameters: body weight, physical
appearance, occurrence of unprovoked behavior, and
blunted or exaggerated responses to external stimuli. At the
age of 15 months all animals were killed with an overdose
of sodium pentobarbital (150 mg/kg) and transcardially
perfused with heparinized (1,000 units/L) 0.01 M PBS at
pH 7.4 and temperature 37O C.
Histological processing and immunohistochemistry
Brains were extracted from skulls and fixed by immersion
in 4% paraformaldehyde in 0.1 M phosphate buffer at
pH 7.4 for 72 h. and then dehydrated in a mixture of 20%
Dimethyl sulfoxide and 20% glycerol in 0.01 PBS at pH 7.4
and temperature 4O C. Brains were cut serially along the
entire rostro-caudal axis using a freezing microtome (Leica
Microsystems, Wetzlar, Germany), into coronal, 40-μm-
thick sections, which were alternately collected into 10
series. Randomly selected series of sections were used for
the following histological and immunohistochemical proce-
dures: Thioflavin-S (Th-S) stain to visualize fibrillar compo-
nent of Aβ parenchymal plaques and cerebral amyloid
angiopathy (CAA); anti-Aβ immunohistochemistry using
HJ3.4 mAb (1:250) [19, 23]; Perls’ Prussian blue stain to
detect perivascular ferric iron deposition [24–26]; and a
combination of anti-Iba1 immunostaining (anti-Iba1 rabbit
polyclonal antibody 1:1,000; Wako Chemicals USA Inc.,
Richmond VA) or anti-CD68 immunostaining (anti-CD68
rabbit polyclonal antibody 1:250; Abcam Inc., Cambridge,
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MA) and Th-S to characterize microglia response in associ-
ation with fibrillar Aβ parenchymal plaques. The intensity
of HJ3.4 immunostaining was enhanced by formic acid
(FA) pretreatment and the immunohistochemistry protocol
was concluded using M.O.M. 3,3'-diaminobenzidine (DAB)
kit (Vector Laboratories; Burlingame, CA) as per manufac-
turer manual. The anti-CD68 and anti-Iba1 immunostain-
ing protocol was concluded using mouse anti-rabbit IgG
biotinylated antibody (1:500) followed by streptavidin con-
jugated Cy3 fluorochrome (1:200), as previously described
[19]. Additional series from selected brains were double-
stained with Perls’ Prussian blue stain and HJ3.4 anti-Aβ
mAb or Th-S stain to visualize association of VAβ with
hemosiderin deposits. One series of sections from five ran-
domly selected APP/ε4 mice treated with 10D mAb and
TY11-15 IgG controls were immunostained with 4G8 mAb
(1:2,000) (Covance; Princeton, NJ) directed against Aβ
residues 17–24 [20, 27]. In this case, sections were also FA
pretreated to enhance Aβ immunodetection and the stain-
ing procedure was concluded using M.O.M. DAB kit. This
was done to verify that 10D5 mAb does not obscure
binding of HJ3.4 mAb to deposited Aβ since both mAbs
are directed against the N-terminus of Aβ while 4G8 mAb
binds a central Aβ epitope.
Analysis of fibrillar parenchymal plaque load and cerebral
amyloid angiopathy (CAA) load
These metrics were determined using an unbiased, whole-
section quantification approach. The entire cross-sectional
profile of the right hemisphere stained with Th-S, was
photographed under × 4 objective magnification using a
high-sensitivity, cooled, monochrome DS-Qi1Mc camera
attached to 80i Nikon fluorescent microscope (Nikon Corp.
Tokyo, Japan). Adjacent frames were combined into a
single image using the photo-stitching function of the NIS
Elements imaging software (Nikon Corp. Tokyo, Japan)
and analyzed with the help of NIH Image J v 1.47 image
processing software package (Bethesda, MD). The cross-
sectional profiles of the brain cortex or the hippocampus
was manually outlined on the hemispheric images and the
load of all Th-S positive Aβ deposits (defined as the per-
centage of a brain structure profile occupied by Th-S posi-
tive lesions) was automatically thresholded and filtered
according to the preset algorithm to discriminate nonspe-
cific staining. Then Th-S positive vascular deposits consti-
tuting CAA were manually eliminated from digitized
images and the thresholding procedure was repeated to
quantify the load of fibrillar parenchymal Aβ plaques only.
The CAA load was then calculated as the difference be-
tween the load of all Th-S positive Aβ deposits and the load
of Th-S positive parenchymal Aβ plaques for a given brain
section. The brain cortex was analyzed on three coronal
cross-sectional profiles per brain, which were taken from
levels of the anterior commissure, the rostral portion of the
hippocampus (Fig 1a), and the mammillary bodies and cor-
respond to the following stereotactic coordinates: Bregma
0 mm, Bregma −1.25 mm, and Bregma −2.8 mm, respect-
ively. The hippocampus was analyzed on serial coronal
cross-sectional profiles through the dorsal hippocampus.
Quantification of immunopositive Aβ parenchymal
plaque load
The load of Aβ plaques immunostained with HJ3.4 or
4G8 anti-Aβ mAbs in the brain cortex was analyzed on
three coronal cross-sectional profiles per brain corre-
sponding to the aforementioned anatomical levels. The
load of immunopositive Aβ plaques in the hippocampus
was analyzed on serial coronal cross-sectional profiles
through the dorsal hippocampus. Serial microphotographs
covering the entire cross-sectional profile of the brain cor-
tex or the hippocampus were taken under ×20 magnifica-
tion using DS-Fi1 color camera attached to 80i Nikon
microscope. Captured photographs were combined into a
single image using the photo-stitching function of the NIS
Elements Imaging Software, and automatically thre-
sholded and filtered by size according to the preset algo-
rithm to discriminate nonspecific staining and Aβ positive
capillaries using NIH Image J v 1.47 (Bethesda, MD). The
load of immunopositive parenchymal Aβ plaques per
brain was calculated as the average of load values obtained
from all three analyzed brain sections.
Assessment of cerebral capillary Aβ (CCA)
Prevalence of HJ3.4-immunoreactive capillaries was an-
alyzed on three coronal cross-sectional profiles through
the brain cortex at the aforementioned anatomical
levels and on three to four subsequent coronal cross-
sectional profiles through the thalamus. Aβ immu-
nopositive capillaries (defined as vessels with diameter
< 8 μm [28, 29]) were manually counted at 40× ob-
jective magnification and their number was expressed
as n/mm2.
Microglia analysis
The analysis was performed on sections immunostained
against Iba1 or CD68 antigen and counterstained with Th-
S. Microphotographs of the brain cortex were taken at × 20
objective magnification under Tetramethylrhodamine (for
Iba1/Cy3 and CD68/Cy3) and Fluorescein isothiocyanate
(for Th-S) channels of 80i Nikon fluorescent microscope
(Nikon Corp. Tokyo, Japan) using DS-Qi1Mc monochrome
camera (Nikon Corp. Tokyo, Japan). The load of Iba1 and
CD68 positive cells (defined as the percentage of a micro-
photograph area occupied by anti-Iba1 or anti-CD68 posi-
tive immunostaining) was automatically thresholded and
filtered according to the preset algorithm to discriminate
nonspecific staining using NIH Image J v 1.47 (Bethesda,
MD). To control for variable Aβ parenchymal plaque load
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across APOE genotypes the Iba1 load and the CD68 load
was divided by the load of Th-S positive Aβ parenchymal
plaques determined on the same microphotograph as
described above.
Analysis of perivascular hemosiderin deposits
A complete series of brain coronal cross-sections evenly
spaced 400 μm apart from each animal was analyzed.
Such series typically includes 13–15 sections, which
Fig. 1 Analysis of the fibrillar plaque load. APOE genotype differentially modulates fibrillar plaque load and its reduction in response to 10D5 mAb
treatment. a Representative microphotographs of Thioflavin-S (Th-S) stained coronal brain sections at the level of the rostral hippocampus from
untreated age-matched (Age control) mice, and mice receiving an isotype control IgG2a antibody TY11-15 or 10D5 anti-Aβ mAb. Unbiased
quantification of Th-S positive, fibrillar Aβ plaque load in the brain cortex (b) and in the hippocampus (c). Values shown in (b) and (c) represent
mean ± SEM from 7 to 13 animals in TY11-15 and 10D5 mAb treated groups and 5 to 11 mice in Age control groups per APOE genotype. (b),
and (c) p < 0.0001 (one-way analysis of variance); *p < 0.05, **p < 0.01, and ****p < 0.0001, TY11-15 control vs. 10D5 mAb treatment for matching
APOE genotypes (Sidak’s post hoc test). Differences between Age control and TY11-15 groups were non-significant for all matching APOE
genotypes (Sidak’s post hoc test); not shown on the graph. ####p < 0.0001, TY11-15 APP/ε4 control vs. TY11-15 APP/ε2 or APP/ε3 controls (Sidak’s
post hoc test). ♦p < 0.05, TY11-15 APP/ε2 control vs. TY11-15 APP/ε3 control (Sidak’s post hoc test). ++++p < 0.0001, 10D5 mAb treated APP/ε4 mice
vs. 10D5 mAb treated APP/ε2 or APP/ε3 mice (Sidak’s post hoc test). Differences between 10D5 mAb treated APP/ε2 and APP/ε3 mice were
non-significant (Sidak’s post hoc test); not shown on the graph. Scale bars 750 μm (a)
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were stained with Perls’ Prussian blue method without
counterstain to maximize sensitivity of detection. Man-
ual count of perivascular hemosiderin deposits in all
brain structures (Additional file 2: Figure S2 A-C) was
performed under × 20 objective magnifications. De-
posits ≥ 15 μm in diameter were classified as large.
Measurement of the serum cholesterol level
At the conclusion of the experiment blood samples were
collected and centrifuged to separate serum. The total
serum cholesterol concentration was measured using a
standard enzymatic assay based on the Cholesterol E kit
(Wako Diagnostics, Richmond, VA) as previously described
[19, 24].
Statistical analysis
Distribution of data within all data sets was analyzed with
Kolmogorov-Smirnov and Shapiro-Wilk tests. Multiple data
sets conforming to the normal distribution were first com-
pared for statistical differences using one-way analysis of
variance, which was then followed by Sidak's post hoc test
for comparison between selected data sets. Multiple data
sets, which did not conform to the normal distribution,
were compared using Kruskal-Wallis one-way analysis of
variance by ranks followed by Dunn’s test for post hoc
comparison between selected data sets. All statistical ana-
lyses were performed using GraphPad Prism v 6.05 (Graph-
Pad Software, Inc.). All data were reported as the mean and
the standard error of the mean (SEM) per APOE genotype
and treatment arm for each outcome measure.
Results
APOE genotype modulates reduction in parenchymal
plaque load by Aβ immunotherapy
APOE targeted replacement APPSW/PS1dE9 mice faithfully
reflect the differential effect of APOE alleles on Aβ brain
deposition. At the age of 15 months, the load of Th-S posi-
tive, fibrillar plaques in the brain cortex of TY11-15 control
APP/ε4 mice was 3.1 and 2.6 fold higher than that in
TY11-15 control APP/ε2 and APP/ε3 mice, respectively,
while in the hippocampus it was 2.7 and 2.1 fold higher, re-
spectively (p < 0.0001) (Fig. 1a-c). The load of immunoposi-
tive Aβ plaques in the brain cortex of TY11-15 control
APP/ε4 mice was 1.3 and 1.6 fold higher, than that in
TY11-15 control APP/ε2 and APP/ε3 mice, respectively,
while in the hippocampus it was 1.5 and 1.7 fold higher, re-
spectively (p < 0.001) (Fig. 2a-d). The plaque load in the
brain cortex for matching APOE genotypes was higher than
that in the hippocampus and the fold difference ranged
from 1.4 (APP/ε3) to 1.8 (APP/ε4) for fibrillar plaque load
(p < 0.01) and from 1.1 (APP/ε4) to 1.3 (APP/ε2) for immu-
nopositive Aβ plaque load (p < 0.05 for APP/ε2 only). As
we found no statistically significant differences in the load
of fibrillar and immunopositive Aβ plaques between male
and female mice of the same APOE genotype, thus animals
of both sexes were combined for all analyses.
10D5 mAb immunization decreased both fibrillar and
immmunopositive Aβ parenchymal plaque loads. The de-
gree of reduction relative to TY11-15 controls was compar-
able across all three APOE genotypes. Thus, the fibrillar
plaque load in the brain cortex in 10D5 mAb treated APP/
ε2, APP/ε3, APP/ε4 mice was reduced by 27.7% (p < 0.01),
24.4% (p < 0.01), and 22.7% (p < 0.0001) of the TY11-15
control mean value for matching APOE genotype (Fig. 1a,
b), respectively; while the load of Aβ immunopositive pla-
ques was reduced by 43.7% (p < 0.0001), 36.0% (p < 0.01),
and 44.3% (p < 0.0001) (Fig. 2a, b), respectively. Similarly,
the load of fibrillar plaques in the hippocampus of 10D5
mAb treated APP/ε2, APP/ε3, APP/ε4 mice was decreased
by 26.7% (p < 0.05), 34.0% (p < 0.01), and 42.5% (p < 0.0001)
of the TY11-15 control mean value for matching APOE
genotype (Fig. 1a, c), respectively; while the load of Aβ
immunopositive plaques was lowered by 38.7% (p < 0.001),
30.1% (p < 0.05), and 38.3% (p < 0.0001) (Fig. 2c, d), respect-
ively. However, given significantly higher plaque load base-
line in APP/ε4 mice, the absolute plaque load reduction
effected by same dose of 10D5 mAb was incomparably
higher in APP/ε4 mice than in other genotypes. Thus, the
fibrillar plaque load in the brain cortex was reduced from
1.93 ± 0.05% of the cortical cross-sectional area in TY11-15
APP/ε4 controls to 1.49 ± 0.06% in 10D5 mAb treated
APP/ε4 mice (absolute reduction = 0.44%), while the load
of immunopositive Aβ plaques was reduced from 2.67 ±
0.07% to 1.49 ± 0.09% between TY11-15 and 10D5 mAb
groups, respectively (absolute reduction = 1.18%). For com-
parison in APP/ε2 and APP/ε3 mice the absolute reduction
in the fibrillar plaque load in the brain cortex was 0.17%
and 0.18%, respectively; while the absolute reduction in the
load of Aβ immunopositive plaques was 0.89% and 0.61%,
respectively. Analogously, the fibrillar plaque load in the
hippocampus of APP/ε4 mice was reduced from 1.08 ±
0.10% of the hippocampal cross-sectional area in TY11-15
controls to 0.62 ± 0.05% in 10D5 mAb treated mice (abso-
lute reduction = 0.46%), while the load of immunopositive
Aβ plaques was reduced from 2.43 ± 0.15% to 1.50 ± 0.14%
between TY11-15 and 10D5 mAb groups, respectively (ab-
solute reduction = 0.93%). In APP/ε2 and APP/ε3 mice the
absolute reduction in fibrillar plaque load in the hippocam-
pus was 0.11% and 0.18%, respectively; while the absolute
reduction in the load of Aβ immunopositive plaques was
0.62% and 0.42%, respectively. Despite greater treatment
effect seen in APP/ε4 mice, post-treatment load of both
fibrillar and immunopositive Aβ parenchymal plaques in
APP/ε4 mice remained significantly higher than these in
10D5 mAb treated APP/ε2 and APP/ε3 mice (Fig. 1b, c and
Fig. 2b, d).
We found no statistically significant differences between
values of fibrillar plaque loads in the brain cortex and in
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the hippocampus between TY11-15 isotype control IgG2a
antibody treated mice and untreated age-matched mice
for corresponding APOE genotypes (Fig. 1a-c). Likewise
the loads of immunopositive Aβ plaques in TY11-15 con-
trol and untreated age-matched mice for corresponding
APOE genotypes were similar (Fig. 2a-e).
Since 10D5 mAb used for immunotherapy and HJ3.4
mAb used for immunohistochemistry are both directed
against the N-terminus of Aβ we immunostained brain
section from TY11-15 control and 10D5 mAb treated
APP/ε4 mice with 4G8 mAb directed against mid-
portion of Aβ [27] and compared Aβ plaque load on im-
munostaining with both antibodies. This analysis was
done to eliminate unlikely possibility that 10D5 mAb
hinders the HJ3.4 epitope resulting in reduced ability to
detect plaques. Average values of parenchymal Aβ
plaque loads revealed by 4G8 mAb immunostaining
were 2.57% ± 0.10% and 1.49% ± 0.09 in TY11-15 control
Fig. 2 Analysis of the parenchymal Aβ plaque load. Differential effects of APOE genotype on Aβ plaque load and its reduction effected by 10D5
mAb treatment. Representative microphotographs of coronal brain sections through the somatosensory cortex (a) and the dorsal hippocampus
(c) from untreated age-matched (Age control) mice, and mice receiving an isotype control IgG2a antibody TY11-15 or 10D5 anti-Aβ mAb. Aβ
plaques were immunostained with an antibody against the N-terminus of Aβ following formic acid treatment of the sections. Unbiased analysis
of the parenchymal Aβ plaque load in the brain cortex (b), and in the hippocampus (d) revealed by anti-Aβ immunostaining. Values shown in (b)
and (d) represent mean ± SEM from 8 to 12 animals in TY11-15 and 10D5 mAb treated groups and 5 to 10 mice in Age control groups per APOE
genotype. (b) and (d) p < 0.0001 (one-way analysis of variance); *p < 0.05, **p < 0.01, and ****p < 0.0001, TY11-15 control vs. 10D5 mAb treatment
for matching APOE genotypes (Sidak’s post hoc test). Differences between Age control and TY11-15 groups were non-significant for all matching
APOE genotypes (Sidak’s post hoc test); not shown on the graph. ###p < 0.001 and ####p < 0.0001, TY11-15 APP/ε4 control vs. TY11-15 APP/ε2 or
APP/ε3 controls (Sidak’s post hoc test). ♦♦p < 0.01, TY11-15 APP/ε2 control vs. TY11-15 APP/ε3 control (Sidak’s post hoc test). ++p < 0.01, 10D5 mAb
treated APP/ε4 mice vs. 10D5 mAb treated APP/ε2 or APP/ε3 mice (Sidak’s post hoc test). Differences between 10D5 mAb treated APP/ε2 and
APP/ε3 mice were non-significant (Sidak’s post hoc test); not shown on the graph. Scale bars 50 μm (A) and 75 μm (c)
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and 10D5 mAb treated APP/ε4 groups; respectively; and
they were not significantly different from values obtained
with HJ3.4 mAb for the same animal groups (Additional
file 1: Fig. S1 A, B).
10D5 mAb exerts enhanced effector response on
microglia in the setting of the APOE ε4 allele
Expression of two microglia markers, Iba1 and CD68 were
compared across APOE genotypes and treatment arms.
Iba1 is a calcium-binding protein specifically expressed by
microglia and macrophages and its expression increases
with microglia activation [30]. CD68 antigen is a
glycoprotein localized to the lysosomal membrane in
microglia and blood derived macrophages and is up regu-
lated in actively phagocytic cells [31]. Activated microglia
expressing both markers were found in the vicinity of Th-S
positive plaques in control animals of all APOE genotypes
but their loads were significantly higher in APP/ε4 mice
compared to APP/ε2 and APP/ε3 mice. The load of Iba1
positive cells in the brain cortex of TY11-15 APP/ε4 con-
trol mice was 2.9 and 2.6 fold greater than in TY11-15
APP/ε2 and APP/ε3 control mice (p < 0.0001) (Fig. 3a, b),
respectively; while the CD68 load was approximately 2.9
greater (p < 0.0001) (Fig. 3d, e). The isotype control
Fig. 3 Characterization of microglia response. The APOE ε4 allele is associated with enhanced microglia activation resulting from 10D5 mAb
immunization compared to other APOE genotypes. a Representative microphotographs of Iba1 positive microglia in the brain cortex from untreated
Age control APP/ε2 and APP/ε4 mice, and APP/ε2 and APP/ε4 mice receiving TY11-15 an IgG2a isotype control antibody or 10D5 anti-Aβ mAb.
Anti-Iba1 immunostaining is visualized by red color while green color reflects counterstaining of fibrillar Aβ parenchymal plaques with Th-S. b Unbiased
quantification of Iba1 positive cell load in the neocortex and (c) Iba1 load normalized to Th-S positive fibrillar plaque load across APOE genotypes and
treatment arms. d Representative microphotographs of CD68 positive microglia associated with Aβ parenchymal plaques from Age control, TY11-15
or 10D5 treated APP/ε2 and APP/ε4 mice. Anti-CD68 immunostaining and Th-S staining of fibrillar Aβ plaques are visualized by red and green colors,
respectively. e Unbiased quantification of CD68 positive cell load in the neocortex and (f) CD68 positive cell load normalized to Th-S positive
parenchymal plaque load across APOE genotypes and treatment arms. Values shown in (b), (c), (e), and (f) represent mean ± SEM from n = 11-14
measurements/group. (b), (c), (e), and (f) p < 0.0001 (one-way analysis of variance); *p < 0.05, **p < 0.01, and ****p < 0.0001, TY11-15 control vs. 10D5
mAb treatment for matching APOE genotype (Sidak’s post hoc test). Differences between Age control and TY11-15 groups were non-significant for all
matching APOE backgrounds (Sidak’s post hoc test); not shown on the graph. ####p < 0.0001, TY11-15 APP/ε4 control vs. TY11-15 APP/ε2 or APP/ε3
controls (Sidak’s post hoc test). ++p < 0.01 and ++++p < 0.0001, 10D5 mAb treated APP/ε4 mice vs. 10D5 mAb treated APP/ε2 or APP/ε3 mice (Sidak’s
post hoc test). ♦p < 0.05, 10D5 mAb treated APP/ε2 mice vs. 10D5 mAb treated APP/ε3 mice (Sidak’s post hoc test). Scale bars 50 μm (a) and 25 μm (d)
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antibody TY11-15 treatment had no significant effect on
Iba1 and CD68 loads as their values were similar in TY11-
15 control mice and untreated age-matched mice of corre-
sponding APOE genotypes.
Passive immunization with 10D5 mAb effected signifi-
cant microglia response across all APOE genotypes. The
Iba1 load in 10D5 mAb treated APP/ε2, APP/ε3, and
APP/ε4 mice was increased by 23.8% (p < 0.05), 39.0%
(p < 0.05), and 39.4% (p < 0.0001) relative to the mean
Iba1 load in TY11-15 controls of corresponding APOE
genotypes, respectively (Fig. 3a, b); while the CD68 load
was increased by 29.5% (p < 0.05), 32.8% (p < 0.05), and
23.3% (p < 0.0001), respectively (Fig. 3d, e).
Since the load of Iba1 and CD68 positive microglial was
distinguishably the greatest in TY11-15 APP/ε4 mice,
which also show the highest Aβ plaque load, we addition-
ally analyzed the ratio of Iba1 and CD68 loads to the load
of Th-S-positive parenchymal plaques for the same test
area (Fig. 3c, f ). This analysis enabled us to compare the
level of microglia activation across APOE genotypes. We
found no statistically significant differences in the Iba1/
Th-S ratio and in the CD68/Th-S ratio between TY11-15
control and untreated age-matched control mice across all
APOE genotypes suggesting that both Iba1 load and CD68
load correlate with fibrillar plaque load. 10D5 mAb
immunization effected significant increase in both the
Iba1/Th-S ratio and the CD68/Th-S ratio. The magnitude
of increase was comparable between APP/ε2 and APP/ε3
genotypes while in APP/ε4 mice it was substantially
higher. In 10D5 mAb treated APP/ε4 mice the Iba1/Th-S
ratio became 1.4 fold higher than in 10D5 mAb treated
APP/ε2 and APP/ε3 mice (p < 0.0001), while the CD68/
Th-S ratio was 1.33 (p < 0.0001) and 1.21 (p < 0.01) fold
higher, respectively (Fig. 3c, f ).
Using the combination of anti-Iba1 immunostaining and
Th-S counterstaining enabled us also to analyze morph-
ology of microglia across APOE genotypes and treatment
arms. Microglia associated with fibrillar plaques displaying
features of activated microglia/macrophage ie. enlargement
and rounding of the perikaryon and shortening of processes
to their nearly disappearance, were observed in untreated
age-matched and TY11-15 controls of all APOE back-
grounds (Fig. 3a). 10D5 mAb treatment was associated with
increased periplaque microglia recruitment and enhance-
ment of its morphological activation features. This effect
was significantly more pronounced in APP/ε4 mice than in
other genotypes (Fig. 3a). In parallel to peri-plaque
localization of activated microglia demonstrated by anti-
Iba1 immunostaining, there also was noticeable peri-plaque
localization of anti-CD68 immunostaining, which highlights
lysosomal component of activated microglia/macrophages
(Fig. 3d). Akin to Iba1 expression the peri-plaque expres-
sion of CD68 antigen increased with 10D5 mAb treatment
across APOE genotypes but the increase was the most
pronounced in 10D5 treated APP/ε4 mice. Peri-plaque re-
cruitment of Iba1 positive activated microglia/macrophages
and accompanying upsurge of CD68 expression in 10D5
mAb treated mice was associated with reduced plaque
diameter as demonstrated by double anti-Iba1/Th-S and
anti-CD68/Th-S stainings (Fig. 3a, d). We also observed
Iba1 positive activated microglia and CD68 positive puncta,
which were dissociated from Th-S positive plaque. They
likely define activated microglia engaged with diffuse,
immnunopositive Aβ plaques lacking fibrillar component.
Their load also became markedly increased with 10D5
mAb treatment.
APOE genotype has strong differential effect on VAβ
burden and its reduction with Aβ immunotherapy
Two forms of Aβ angiopathy were observed in brains of
APOE targeted replacement APPSWE/PS1dE9 mice and
they were analyzed separately. The first type was CAA de-
fined as Th-S positive deposits of fibrillar Aβ in walls of
meningeal arteries and arteries penetrating the brain cor-
tex (Fig. 4a). CAA load was quantified in the brain cortex
on Th-S stained sections and defined as the percent of the
cross-sectional area of the cortex occupied by CAA laden
vessels. The second type of Aβ angiopathy concerned im-
munoreactive Aβ deposits along walls of capillary vessels,
which were Th-S negative (CCA) (Fig. 5a). CCA incidence
was analyzed by calculating a number of Aβ immunoposi-
tive capillary profiles per mm2 in the brain cortex where
they appeared in abundance across all APOE genotypes.
In addition, CCA was analyzed in the thalamus as in APP/
ε2 mice it was associated with outstanding number of
perivascular hemosiderin deposits.
There was no significant difference in the CAA load be-
tween untreated age-matched and TY11-15 control mice
for each of APOE genotypes analyzed. However across the
TY11-15 control groups, APP/ε4 mice showed two fold
higher CAA load than APP/ε3 mice (p < 0.01) (Fig. 4a, b).
In contrast to APP/ε3 and APP/ε4 lines, in APP/ε2 mice
CAA laden arteries were rarely occurring and were
present in only some of the mice which precluded reliable
quantification of the CAA load in this genotype (Fig. 4a).
CAA laden vessels were rarely and inconsistently observed
in the hippocampus and in subcortical structures includ-
ing the thalamus in mice of any APOE genotype. 10D5
mAb treatment reduced the CAA load in the brain cortex
in APP/ε3 and APP/ε4 mice by 56% (p < 0.05) and 71% (p
< 0.01) relative to the mean CAA load value in TY11-15
controls of corresponding genotypes. However, given sig-
nificantly higher CAA load baseline in APP/ε4 mice the
absolute CAA load reduction in APP/ε4 mice was 2.5 fold
higher than that in APP/ε3 mice. Thus, the CAA load in
APP/ε4 animals was reduced from 0.41 ± 0.03% in TY11-
15 controls to 0.11 ± 0.02% in 10D5 mAb treated group
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(absolute CAA load reduction = 0.30%) while in APP/ε3
mice the absolute reduction in the CAA load was 0.12%.
Unlike CAA, which was the most prevalent in APP/ε4
mice, the greatest abundance of CCA was associated with
the APOE ε2 allele (Fig. 5a-c). The density of CCA associ-
ated capillary profiles per mm2 in the brain cortex of APP/
ε2 TY11-15 control mice was 1.9 and 1.3 fold higher than
these in the brain cortex of APP/ε3 (p < 0.0001) and APP/
ε4 (p < 0.05) TY11-15 controls, respectively; while in the
thalamus of APP/ε2 TY11-15 controls the average density
of CCA associated capillary profiles per group was 13.1 and
5.3 fold higher than in the thalamus of APP/ε3 (p < 0.0001)
and APP/ε4 (p < 0.001) TY11-15 control mice, respectively.
There was no statistically significant difference in the CCA
incidence between untreated age-matched and TY11-15
control mice in the brain cortex and in the thalamus for
any of matching APOE genotype. One needs to mention
that CCA was absent in the thalamus of two thirds of
control APP/ε3 mice and of one half of control APP/ε4
mice. Besides the thalamus, the incidence of CCA in other
subcortical structures was scanty especially in APP/ε3 and
APP/ε4 mice, thus no other structure specific quantification
was performed.
10D5 mAb treatment effected significant CCA reduction
across all three APOE genotypes. In the brain cortex of
APP/ε2 and APP/ε3 mice the density of Aβ immunoposi-
tive capillary profiles was reduced approximately two-fold
(p < 0.001 and p < 0.05; respectively), while in the brain cor-
tex of APP/ε4 mice it was reduced by 1.6 fold (p < 0.05).
10D5 mAb treatment reduced CCA in the thalamus of
APP/ε2 mice 8.5 fold (p < 0.0001). Marked reduction also
was observed in the thalamus of APP/ε3 and APP/ε4 mice,
but it did not reach statistical significance as the data did
not conform to normal distribution hence weaker non-
parametric statistical analysis was used.
APOE ε2 and ε3 alleles show opposing effect on the risk
of cerebral microhemorrhages
Perivascular hemosiderin deposits, reflecting ensued
microhemorrhages, were found associated both with CAA
and CCA positive vessels (Fig. 6a, b). They frequently oc-
curred in untreated age-matched mice of all APOE geno-
types and their number did not increase in TY11-15
treated control animals (Fig. 7a-d). There were no statisti-
cally significant differences in the number of the total
brain hemosiderin deposits, the number of deposits sub-
classified as small and large (with cut off ≥ 15 μm in diam-
eter), and the fraction of deposits localized to the
thalamus between TY11-15 treated APP/ε2 and APP/ε4
mice (Fig. 7a-d). In contrast, untreated age-matched and
TY11-15 APP/ε3 control mice had approximately two-
fold less hemosiderin deposits for each listed category
compared to APP/ε2 and APP/ε4 TY11-15 controls.
10D5 mAb treatment resulted in a significant increase in
the number of hemosiderin deposits yet the magnitude of
this effect was differentially modulated by the APOE
genotype. In APP/ε3, and APP/ε4 mice, an increase by 12.4
and 15.6 deposits per brain on average was observed,
Fig. 4 CAA analysis. APOE genotype differentially modulates the CAA load and its reduction during 10D5 mAb immunization. a Demonstration of
CAA across APOE genotype spectrum. Representative microphotographs of Th-S stained coronal brain sections through the somatosensory cortex
from untreated age-matched (Age control) mice, and mice receiving TY11-15 an isotype control IgG2a antibody or 10D5 anti-Aβ mAb. An arrow
indicates a solitary CAA positive vessel in Age control APP/ε2 mouse. Arrowheads show long segments of CAA laden vessels in APP/ε4 mice and
their reduction with 10D5 mAb treatment. b Mean (± SEM) of CAA load quantified in the brain cortex (n = 8-12/group). (b) p < 0.0001 (one-way
analysis of variance); *p < 0.05, and ****p < 0.0001, TY11-15 control vs. 10D5 mAb treatment for matching APOE genotypes (Sidak’s post hoc test).
##p < 0.01, APP/ε4 TY11-15 control vs. APP/ε3 TY11-15 control (Sidak’s post hoc test). Differences between Age control and TY11-15 groups were
non-significant for matching APOE genotypes (Sidak’s post hoc test); not shown on the graph. Scale bar 100 μm (a)
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respectively; bringing their number in APP/ε3 mice from
20.5 ± 1.9 per brain in TY11-15 controls to 32.9 ± 3.8 per
brain in 10D5 mAb treatment group (p < 0.05), while in
APP/ε4 mice, from 41.1 ± 4.6 per brain in TY11-15 controls
to 56.7 ± 4.1 per brain in the 10D5 mAb treatment group
(p < 0.01) (Fig. 7a). The increase only concerned small de-
posits (Fig. 7b), while the number of large deposits did not
change in either APP/ε3 or APP/ε4 mice (Fig. 7b, c). Differ-
ences in the number of all hemosiderin deposits and small
hemosiderin deposits between 10D5 mAb treated APP/ε3
and APP/ε4 mice were statistically significant (p < 0.0001
and p < 0.01, respectively) (Fig. 7a, b). In APP/ε2 mice
10D5 mAb treatment caused a nearly two-fold higher up-
surge in the number of hemosiderin deposits compared to
APP/ε3 and APP/ε4 mice. The count of all hemosiderin de-
posits was increased on averaged by 27.0 per brain bringing
it from 42.5 ± 3.8 per brain in TY11-15 controls to 69.5 ±
4.4 per brain in 10D5 mAb treated group (p < 0.0001)
(Fig 7a, b). Unlike other APOE genotypes, APP/ε2 mice ex-
perienced an increase both in the number of small and
large hemosiderin deposits. The count of large hemosiderin
deposits was increased on average by 7.3 per brain from
3.7 ± 0.9 in TY11-15 controls to 11.0 ± 1.4 in 10D5 treated
mice (a nearly three-fold increase) (p < 0.0001) (Fig 7c).
The bulk of perivascular hemosiderin deposits was found
in the brain cortex (Additional file 2: Figure S2 A-C). In
Age control and TY11-15 control APP/ε3 and APP/ε4 mice
they constituted between 65 to 70% of the brain total
hemosiderin deposits, while in Age control and TY11-15
control APP/ε2 mice 53% and 58%, respectively. As com-
pared to other APOE genotypes APP/ε2 mice showed
greater number of hemosiderin deposits to the thalamus. In
APP/ε2 TY11-15 control mice 14.9 ± 2.8% of all brain he-
mosiderin deposits was found in the thalamus compared to
5.1 ± 1.9% in TY11-15 APP/ε3 controls (p < 0.05) and 12.3
± 3.1% in TY11-15 APP/ε4 controls (non-significant)
(Fig. 7d). While in APP/ε3 and APP/ε4 mice 10D5 mAb
treatment did not affect the proportion of thalamic hemo-
siderin deposits to all brain deposits, in 10D5 mAb treated
APP/ε2 mice this proportion nearly doubled and it was
27.7 ± 3.6% on average (p < 0.0001) (Fig. 7d; Additional file
2: Figure S2 A). Except for minor increase in the number of
hemosiderin deposits in the hippocampus in APP/ε2 mice,
no other brain structure but the brain cortex in animals of
all APOE genotypes and the thalamus in APP/ε2 mice only,
showed significant regional increase in the number of he-
mosiderin deposits with anti-Aβ passive immunization
(Additional file 2: Figure S2 A-C).
APOE alleles have differential effect on cerebrovascular
disease risk factors in APPSWE/PS1dE9 mice
APOE ε2 targeted replacement mice are established
model of type III hyperlipidemia. APP/ε2 TY11-15 control
mice used in this study showed average total serum
Fig. 5 Characterization of CCA. The APOE ε2 allele is associated with
increased CCA incidence. a Demonstration of CCA in the thalamus of
APP/ε2 mice receiving TY11-15 isotype control IgG2a antibody or 10D5
anti-AβmAb. Arrowheads indicate numerous Aβ immunopositive capillary
vessels (<8 μm in diameter). An arrow in the left panel points at the vessel,
which wall is also Aβ immunopositive, but which was not counted as a
capillary as its diameter exceeded the assumed capillary size cutoff. There
is noticeable reduction in the density of Aβ immunoreactive capillaries
following 10D5 mAb treatment shown on the right panel. Quantitative
analysis of CCA. Shown are means (± SEM) for counts of Aβ
immunopositive capillaries per mm2 in the brain cortex (b) and the
thalamus (c) from 5–8 brains per APOE genotype and 3 sections
per brain. p < 0.0001 (one-way analysis of variance) in (b) and
p < 0.0001 (Kruskal-Wallis H test) in (c); *p < 0.05, and ****p < 0.0001,
TY11-15 control vs. 10D5 mAb treatment for matching APOE
genotypes (Sidak’s post hoc test in [b] and Dunn’s multiple
comparison post hoc test in [c]). +p < 0.05, +++p < 0.001 and ++++p
< 0.0001, TY11-15 APP/ε2 control vs. TY11-15 APP/ε3 or TY11-15
APP/ε4 control groups (Sidak’s post hoc test in [b] and Dunn’s
multiple comparison post hoc test in [c]). #p < 0.05 in (b), TY11-15
APP/ε3 control vs. TY11-15 APP/ε4 control (Sidak’s post hoc test).
Differences between Age control and TY11-15 control for matching
APOE genotypes in (b) and (c) were non-significant; not shown on
the graph. Scale bar 20 μm (a)
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cholesterol level of 477.3 ± 49.5 mg/dl at the age of 15
months. For comparison total serum cholesterol level in
TY11-15 control APP/ε3 and APP/ε4 mice was 83.8 ±
4.7 mg/dL and 97.9 ± 7.7 mg/dL, respectively (p < 0.0001
vs. APP/ε2) (Fig. 8a ). APP/ε2 mice were also obese. The
average weight of APP/ε2 TY11-15 control mice was 46.6
± 0.8 g, while average weight of TY11-15 control APP/ε3
and APP/ε4 mice was 33.6 ± 1.6 g and 35.9 ± 1.5 g, re-
spectively (p < 0.0001 vs. APP/ε2) (Fig. 8b). Neither serum
cholesterol level nor animal weight was significantly chan-
ged with 10D5 mAb treatment. No significant differences
in respect to total serum cholesterol level and animal body
weight between untreated age-control and TY11-15 con-
trol mice for matching APOE genotypes were observed.
Discussion
APOE genotype critically affects the burden of Aβ path-
ology in sporadic AD. ApoE isoforms encoded by various
APOE alleles differentially influence the rate of soluble Aβ
clearance from the brain interstitial space and formation
of Aβ parenchymal plaques and VAβ [32, 33]. Our study
provides novel evidence that APOE genotype also
differentially affects multiple aspects of response to Aβ
immunotherapy. Firstly, we observed that APOE genotype
is associated with variable reduction in the load of Aβ par-
enchymal plaques and APP/ε4 mice had greater reduction
in absolute Aβ plaque load values than APP/ε2 and APP/
ε3 mice. The reduction concerned both Th-S positive, (fi-
brillar) and immunopositive Aβ (total) plaque loads with
the later metric showing greater change than the former
across all APOE genotypes. As the immunopositive Aβ
plaque load is inclusive of Th-S positive plaques this
suggests that stimulated by 10D5 mAb microglia clear dif-
fuse component of Aβ plaques more effectively than they
do fibrillar Aβ aggregates. However, despite enhanced
treatment effect in APP/ε4 mice the post-treatment Aβ
plaque load in these mice and especially the fibrillar Aβ
plaque load, remained significantly higher than in APP/ε2
and APP/ε3 mice, what is a result of distinguishably
greater Aβ plaque load, associated with the ε4 allele. This
observation may inform design of future passive
immunization experiments in APP Tg model mice of AD
and clinical trials suggesting specific tailoring of the anti-
Aβ passive immunization protocol in APOE ε4 allele
Fig. 6 Demonstration of perivascular hemosiderin deposits reflecting ensued microhemorrhages. a Shown is an example of hemosiderin deposition
associated with CAA laden vessel in the cerebral cortex of 10D5 mAb treated APP/ε4 animal. The histological section was double-stained with
Thioflavin-S and Pearls’ Prussian blue stain for ferric iron and photographed under fluorescence and bright-field microscopy, respectively. Positive
perivascular hemosiderin stain (arrowhead) was digitally converted to red color and superimposed on green Thioflavin-S stain of CAA (Merge). An arrow
indicates a vessel affected by CAA, without evidence of bleeding. b Representative microphotograph of CCA related hemosiderin deposits (arrowheads)
in the brain cortex of 10D5 mAb-treated APP/ε2 mouse. A coronal section of the cerebral cortex was immunostained with anti-Aβ HJ3.4 mAb and
counterstained with Pearls’ Prussian blue stain. c Examples of large hemosiderin deposits in the thalamus typical of APP/ε2 mice; Pearl’s iron stain without
counterstain. An arrow on the left panel indicates an isolated thalamic hemosiderin deposit in TY11-15 control APP/ε2 animal, while arrowheads on the
right panel point at the cluster of large hemosiderin deposits (≥15 μm in diameter) identified in 10D5 mAb treated APP/ε2 mouse. Abbreviations:
h-hippocampus, t-thalamus. Scale bars: 75 μm (a), 25 μm (b), 500 μm (c)
Pankiewicz et al. Molecular Neurodegeneration  (2017) 12:12 Page 11 of 17
carriers to achieve end-point plaque load reduction level
compared to that expected among non-ε4 allele carriers.
Potential modifications of the immunization protocol may
include increasing antibody dose, earlier commencement
of the treatment and extension of treatment duration.
However one needs to be mindful that escalation of anti-
Aβ mAbs dose in APOE ε4 allele carriers may trigger in-
creased rate of vasculotropic adverse events associated
with immunization [5, 8, 14]. With the advancement of
certain newer anti-Aβ immunotherapies such as Ganta-
nerumab and Aducanumab that appear to lower Aβ
plaque load in humans to a greater extent than seen
previously [6, 8], it will be interesting to see if the effects
of APOE genotype noted here in animal models are also
present in humans.
The primary mechanism of action of 10D5 mAb is
based on its direct binding to deposited Aβ and stimulat-
ing Fc receptor-mediated Aβ plaque removal by activated
microglia and possibly blood derived macrophages [9, 34].
To compare microglial response across APOE genotypes
we immunostained brain sections against Iba1 and CD68
antigens and counterstained them with Th-S for fibrillar
Aβ. Iba1 is a microglia specific marker, which expression
increases with microglia activation and macrophage
Fig. 7 Quantitative analysis of perivascular hemosiderin deposits. APOE genotype differentially modulates occurrence of hemosiderin deposits and
their increase during Aβ immunotherapy with APOE ε2 and APOE ε3 alleles having adverse and protective effects, respectively. Shown are means
(± SEM) for counts of all brain perivascular hemosiderin deposits (a), small perivascular hemosiderin deposits (<15 μm in diameter) (b), large
perivascular hemosiderin deposits (≥15 μm in diameter) (c), and perivascular hemosiderin deposits in the thalamus presented as per cent of all brain
deposits (d) (n = 5-11/group). Hemosiderin deposits were counted on every tenth brain coronal cross-section along the entire rostro-caudal axis of the
brain. (a) through (d) p < 0.0001 (one-way analysis of variance); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, TY11-15 control vs. 10D5 mAb
treatment for matching APOE genotypes (Sidak’s post hoc test). +p < 0.05, and ++++p < 0.0001, 10D5 mAb treated APP/ε2 mice vs. other 10D5 mAb
treated APP/ε3 or APP/ε4 mice (Sidak’s post hoc test). ♦♦p < 0.01, and ♦♦♦♦p < 0.0001, 10D5 mAb treated APP/ε3 mice vs. 10D5 treated APP/ε4 mice
(Sidak’s post hoc test). ●p < 0.05 APP/ε2 TY11-15 control vs. APP/ε3 TY11-15 control (Sidak’s post hoc test). Differences between Age control and
TY11-15 groups were non-significant for all types of hemosiderin deposits for matching APOE backgrounds, so were differences in the count of large
hemosiderin deposits between TY11-15 control and 10D5 mAb treated APP/ε3 and APP/ε4 mice (Sidak’s post hoc test); not shown on the graph
Pankiewicz et al. Molecular Neurodegeneration  (2017) 12:12 Page 12 of 17
transformation [30], while CD68 is a lysosomal/endosomal
membrane glycoprotein up regulated in actively phago-
cytic cells [31]. The load of Iba1 and CD68 positive cells
was significantly higher in Age control and TY11-15 con-
trol APP/ε4 mice compared to APP/ε2 and APP/ε3 con-
trols. Both Iba1 and CD68 loads correlated with the load
of Th-S positive fibrillar deposits and when adjusted for it,
they were comparable across all APOE genotypes in con-
trol animals. Following 10D5 mAb treatment both Iba1
and CD68 loads increased across all APOE genotypes,
however when adjusted for the post-treatment fibrillar
plaque load, they were significantly higher in APP/ε4 mice
than in APP/ε2 and APP/ε3 animals. This finding illus-
trates increased effector function of 10D5 mAb exerted on
microglia in the setting of the APOE ε4 allele. In particular
exaggerated post treatment CD68/Th-S ratio in APP/ε4
mice implies less effective Aβ degradation, which can be
tied to a recent discovery showing that excessive apoE ac-
cumulation within Aβ plaques impairs ability of microglia
to contain plaque load [35]. In fact, we have previously
demonstrated that APP/ε4 and PDAPP/ε4 mice have
greatly increased content of apoE within Aβ deposits com-
pared to the same Tg mice lines expressing other human
APOE alleles [19, 36]. Though microglial cells play pivotal
role in maintaining immunoproteostasis through phago-
cytosis and degradation of misfolded proteins, their pro-
tective function is inseparably associated with immune
activation exerting a chronic, potentially harmful effect on
the regional milieu of neuronal networks [35, 37–39].
Although, APP/ε4 mice show the greatest absolute reduc-
tion in the load of parenchymal Aβ plaques in response to
anti-Aβ immunization as compared to mice of other
APOE genotypes, this occurs at the expense of unparal-
leled microglia response making the post treatment Iba1
and CD68 loads the highest among all experimental
groups. Thus both higher level of microglia activation
driven by higher Aβ plaque load and exaggerated micro-
glia effector response exerted by anti-Aβ immunotherapy
may constitute independent deleterious effects associated
with the ε4 allele, in AD pathogenesis. Increased microglia
activation and associated reduction in Aβ plaque load was
found only in 10D5 mAb immunized groups, while
administration of the isotype control antibody TY11-15
changed neither expression of microglia markers nor
parenchymal plaque load as compared to untreated age-
matched animals of matching APOE genotypes.
Both CAA and CCA variants of VAβ pathology have
been described in AD autopsies and their relative prepon-
derance has been linked to various APOE genotypes [40–
43]. CAA comprises of fibrillar Aβ sandwiched between the
adventitia and the tunica media of cerebral arteries, while
CCA comprises of non-fibrillar Aβ deposits closely associ-
ated with the capillary outer basement membrane. Both
development of CAA and CCA is primarily driven by
neuron derived Aβ, while Aβ produced by myocytes locally
in the tunica media further contributes to CAA develop-
ment (reviewed in [42]). Presence of apoE within CAA
lesions is critical for formation of Aβ fibrillar assemblies
[25]. In this study we found that APOE genotype modulates
development of both CAA and CCA pathology in APP Tg
mice. In accordance to previously published data concern-
ing ε4 allele effect, we found increased CAA load in APP/
ε4 mice [25, 44–46]. Our novel observation here is that the
ε2 allele was associated with greatly reduced CAA load, but
also with enhanced incidence of CCA. Reduced CAA load
in APP/ε2 mice likely reflects limited effect of apoE2
isoform on promoting Aβ fibrillar assemblies within arterial
walls as compared to other human apoE isoforms, which
are associated with higher load of CAA and fibrillar Aβ
plaques [47]. In turn, greater incidence of CCA may be re-
lated to increased amount of soluble Aβ cleared across the
BBB in APP/ε2 animals, which deposit less Aβ in the brain
while maintaining the same level of Aβ production [32]. In
Fig. 8 Analysis of cerebrovascular disease risk factors. APP/ε2 mice
show hypercholesterolemia and obesity. Mean ± SEM of the total
serum cholesterol level (a) (n = 5-10/group) and body weight (b)
(n = 6-16/group) of untreated Age control, TY11-15 treated control,
and 10D5 mAb treated mice determined at the age of 15 months at
the conclusion of the experiment. a and (b) p < 0.0001 (one-way
analysis of variance); ++++p < 0.0001, TY11-15 APP/ε2 vs. TY11-15 APP/
ε3 and APP/ε4 control mice (Sidak’s post hoc test). Differences
between Age control, TY11-15 control, and 10D5 mAb treated mice
were non-significant for matching APOE backgrounds (Sidak’s post hoc
test); not shown on the graph
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fact increased rate of soluble Aβ clearance across the BBB
has been experimentally confirmed in the setting of the
APOE ε2 allele [32, 48]. Vascular disease risk factors includ-
ing hypercholesterolemia and volume overload occurring in
aged APP/ε2 mice effect deterioration of capillary wall
structure and function and likely in tandem with greater
load of soluble Aβ passing across the BBB contribute to
CCA development.
The largest percentage of AD patients with both CAA
and CCA was found among ε4 allele carriers, while
CAA without CCA was more frequent among ε2 and ε3
carriers [40, 42]. In these studies ε3 allele carriers and in
particular ε3 allele homozygotes constituted the largest
percentage among CAA/CCA free cases. Accordingly,
we found that APP/ε3 mice have the lowest incidence of
CCA among all APOE genotypes and their CAA load is
significantly lower than that in APP/ε4 mice demonstrat-
ing protective effect of the ε3 allele against development
of Aβ angiopathy. However, mechanisms underlying
VAβ deposition including preferential development of
CAA and CCA remain elusive and require further eluci-
dation. They likely are a resultant of multiple genetic
features extending beyond APOE genotype as no APOE
allelic variant confers absolute protection against VAβ
deposition [42, 43].
VAβ is detrimental to the function of cerebrovascular
circulation through compromising blood–brain-barrier
integrity [49], effecting hemodynamic dysfunction [29,
50], and facilitating occurrence of spontaneous hemor-
rhages [25, 26, 36]. We found a significant number of
perivascular hemosiderin deposits, reflecting ensued
microhemorrhages, in brains of control mice represent-
ing all APOE genotypes. They were associated both with
CAA and CCA affected vessels. Strikingly the lowest in-
cidence of perivascular hemosiderin deposits was ob-
served among untreated age-matched and TY11-15
control APP/ε3 mice. In APP/ε4 and APP/ε2 controls
the incidence of perivascular hemosiderin deposits was
comparable and statistically significant higher than that
in APP/ε3 controls. In human subjects prevalence of
spontaneous microhemorrhages is high and positively
correlates with advancing age. MRI studies detected
microbleeds in 17.8% of subjects aged 60–69 years and
in 38.3% in subjects who were more than 80 years old
[51, 52]. For comparison an autopsy study reported
histological evidence of ensued microhemorrhages in
92.9% of elderly individuals with mean age of 81.1 ±
10.8 years, which included both AD and non-demented
subjects [53]. Evidence independently supports link of
both the APOE ε4 and ε2 allele with increased risk for
microhemorrhages in humans [51, 52, 54–57]. Both VAβ
and hypertensive or atherosclerotic microangiopathy are
recognized clinical risk factors for cerebral microbleeds,
with the former correlating stronger with bleeding in
cortical/subcortical distribution [58, 59] while the later
with bleeding to deep brain structures including basal
ganglia and thalamic nuclei [60, 61]. APOE ε2 targeted
replacement mice develop type III hyperlipoproteinemia
and spontaneous atherosclerosis [16] as well as volume
overload as a function of their obesity, all of which are
recognized vascular risk factors and may explain in-
creased preponderance to thalamic localization of hemo-
siderin deposits in APP/ε2 mice found in our study.
However, these striking vasculotropic effects observed
here in APP/ε2 mice may not be robustly seen in human
subjects, where ε2 homozygotes constitute only 1% of
the population, with less than 10% of them developing
type III hyperlipoproteinemia, what is linked to distinctly
different contribution of apoE to VLDL formation be-
tween humans and mice [62].
Aβ immunotherapy can ameliorate VAβ burden and im-
prove compromised vascular reactivity [12, 21, 63], but it is
well known to escalate incidence of brain microhemor-
rhages [21, 26]. Both CAA load and CCA incidence were re-
duced in 10D5 mAb treated mice with the strongest effect
on CAA load reduction seen in APPε4 animals and the
strongest effect on CCA incidence seen in APP/ε2 mice. We
also found a profound effect of APOE genotype on Aβ
immunization related microhemorrhages. Surprisingly not
the ε4 allele but the ε2 allele was associated with the greatest
increase in the number of perivascular hemosiderin deposits.
10D5 mAb treated APP/ε2 mice had the highest increase in
the number of all perivascular hemosiderin deposits and also
in the number of deposits in small and large (≥15 μm in
diameter) subcategories. The increase in the total number of
hemosiderin deposits in APP/ε2 mice was approximately
two-fold higher than these in APP/ε3 and APP/ε4 mice.
APP/ε2 mice represented the only APOE genotype where
10D5 mAb immunization increased incidence of large he-
mosiderin deposits, bringing their number to three-fold
value of the control group. Several human autopsy studies
have shown that the ε2 allele is an exacerbating factor of
microhemorrhages among subjects with VAβ pathology and
that this effect is linked to fibrinoid necrosis of vascular wall
specifically associated with the ε2 allele [55–57]. As men-
tioned above APP/ε2 mice also develop hypercholesterol-
emia and atherosclerosis, hence increased susceptibility to
cerebral microhemorrhages and in particular high incidence
of large hemosiderin deposits in APP/ε2 mice associated
with immunotherapy can be a resultant of prevalent VAβ
pathology, anti-Aβ mAb effect, and cerebrovascular risk
factors all cooperatively compromising vascular wall integ-
rity. In contrast, 10D5 mAb treated APP/ε3 and APP/ε4
mice showed only an increase in the number of small hemo-
siderin deposits. Again the post-10D5 treatment number of
hemosiderin deposits in APP/ε3 mice was the lowest among
all APOE genotypes, indicating a relative vasculoprotective
effect of the ε3 allele, which has not been previously
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described in AD patients or APP Tg mice expressing human
APOE alleles.
Exacerbation of VAβ associated microhemorrhages
appears to be associated with propensity of anti-Aβ mAb to
bind deposited Aβ. Thus, application of N-terminus specific
mAbs, which like10D5 binds epitopes exposed in Aβ par-
enchymal plaques and VAβ, but not mAbs, which like
m266 bind the Aβ central domain and do not bind to de-
posited Aβ effect increased hemorrhage incidence [64, 65].
However mAbs binding deposited Aβ are generally more
effective in clearing VAβ [12]. Time course analysis of VAβ-
related events during immunotherapy in PDAPP mice, re-
vealed that a time window for increased incidence of
microhemorrhages can last up to six months, but then their
incidence diminishes drastically, which correlates with
achieving significant clearance of both CAA and CCA [21].
Thus, the risk of brain microhemorrhages related to Aβ im-
munotherapy may be a transient complication and possibly
reduced in individuals with modest VAβ burden, who also
have lower prevalence of spontaneous microbleeds [58, 59].
Conclusions
Utilizing APOE humanized APPSWE/PS1dE9 mice we demon-
strated that APOE alleles differentially modulate various
aspects of response to anti-Aβ immunotherapy including Aβ
load reduction, microglia response, and incidence of cerebral
microhemorrhages. This information can be utilized in
design of clinical trials of anti-Aβ mAbs and other Aβ target-
ing therapeutics in order to maximize potency of studied
approaches and minimize adverse reaction to the treatment.
Additional files
Additional file 1: Figure S1. Comparative analysis of Aβ plaque load
immunostained against N-terminal and central Aβ epitopes revealed no
significant differences. a Representative microphotographs of coronal brain
sections through the somatosensory cortex from the same TY11-15 control,
and 10D5 mAb treated mice of APP/ε4 background, which were
immunostained using HJ3.4 mAb directed against the N-terminus of Aβ and
4G8 mAb directed against the mid-portion of Aβ. b Unbiased analysis of the
parenchymal Aβ plaque load in the brain cortex revealed by HJ3.4 and 4G8
immunostaining. Values represent mean ± SEM from 10 to 12 animals per
group. b p< 0.0001 (one-way analysis of variance); ****p< 0.0001, TY11-15
control vs. 10D5 mAb treatment for matching anti-Aβ immunostains (Sidak’s
post hoc test). Differences between HJ3.4 and 4G8 immunostaining in TY11-15
control and 10D5 mAb treatment groups were non-significant; not shown on
the graph. Scale bar 50 μm (a). (PDF 423 kb)
Additional file 2: Figure S2. Regional analysis of perivascular
hemosiderin deposits identifies the brain cortex in mice of all APOE
genotypes and the thalamus in APP/ε2 mice as brain structures
susceptible to microbleeds associated with anti-Aβ immunization.
Shown are means (± SEM) for counts of all brain perivascular hemosiderin
deposits in the brain cortex, the hippocampus, the basal ganglia, the
corpus callosum, the thalamus, the septum and the midbrain in APP/ε2
(a), APP/ε3 (b), and APP/ε4 mice (c) (n = 5-11/group). Perivascular
hemosiderin deposits were counted on every tenth brain coronal cross--
section along the entire rostro-caudal axis of the brain. a through (c) p <
0.0001 (one-way analysis of variance); *p < 0.05, ***p < 0.001, and ****p <
0.0001, TY11-15 control vs. 10D5 mAb treatment for matching brain
structures and APOE genotypes (Sidak’s post hoc test). For brain structures
where the differences between TY11-15 control and 10D5 mAb treat-
ment groups were not statistically significant p values are not shown. Dif-
ferences between Age control and TY11-15 groups were
non-significant for all structures (Sidak’s post hoc test); p values not
shown on the graph. (PDF 419 kb)
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